Psoriasis

New England CEPAC

Plaque psoriasis is a common disease that causes red, scaly, raised lesions on the skin, most commonly on the elbows, knees, scalp, and back. Psoriasis affects about 2% of the population and significantly decreases health-related quality of life. It is a chronic inflammatory condition associated with systemic diseases.

Interventions of interest:

  • Anti TNF agents: Adalimumab (Humira®, AbbVie), etanercept (Enbrel®, Amgen, Inc.), infliximab (Remicade®, Janssen)
  • Anti IL-17A agents: Secukinumab (Cosentyx®, Novartis), ixekizumab (Taltz®, Eli Lilly and Co.), brodalumab (SiliqTM, Valeant Pharmaceuticals and AstraZeneca)
  • Anti IL-12/23 agent: Ustekinumab (Stelara®, Janssen)
  • Anti PDE4 agent: Apremilast (Otezla®, Celgene)

Included in planned 2018 Condition Update:

  • Anti IL-23 agents: Guselkumab (Tremfya®, Janssen/Johnson & Johnson), tildrakizumab (Sun Pharma)
  • Anti TNF agent: Certolizumab pegol (Cimzia®, UCB)

ASSOCIATED MEETING & MATERIALS

New England CEPAC
July 12, 2018 10am - 4pm ET

Champlain College
Communication & Creative Media (CCM) Building
375 Maple Street
Burlington, VT 05401

The New England CEPAC will convene to review ICER's condition update on therapies for plaque psoriasis. During this meeting, the Council will also review a report on elagolix for endometriosis.

Key Dates

Associated Materials

11/09/2017 – 11/30/2017

12/04/2017

12/04/2017

12/04/2017 – 12/22/2017

01/09/2018

02/20/2018

02/20/2018

04/27/2018

Open to public comment until May 25, 2018. For more information on submitting a public comment, please visit our stakeholder engagement page.


04/27/2018

04/27/2018 – 05/25/2018
Public Comments

06/08/2018
Revised Voting Questions

06/12/2018
Response to Comments

06/12/2018
Evidence Report

07/12/2018
Meeting Agenda

07/27/2018
Final Evidence Report and Meeting Summary


ASSOCIATED MEETING & MATERIALS

New England CEPAC
November 18, 2016 10AM-4PM

The Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115

The New England CEPAC convened to deliberate and vote on evidence presented in ICER's report on treatments for psoriasis.

Key Dates

Associated Materials

06/24/2016

07/15/2016

07/25/2016

09/29/2016

This report was open to public comment until October 20, 2016.


09/29/2016

09/29/2016

11/04/2016

The public comment period on the Draft Evidence Report has closed.


11/04/2016

11/04/2016

11/04/2016

11/18/2016

Public meeting of the New England CEPAC in Boston, MA